Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 8/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261276 | 0.89 | FGFR1 (0.47) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL6551980 | 0.86 | FGFR1 (0.45) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL236000 | 0.85 | FGFR1 (0.51) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL23343373 | 0.85 | FGFR1 (0.44) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL6379845 | 0.83 | FGFR1 (0.43) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL1765906 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL22078831 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL3260493 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL2967556 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6MAPTEP300 | |
| SCHEMBL5016785 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6LMNATHRBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023064223-A1 | TRI-SUBSTITUTED PYRIDINES | GOSSAMER BIO SERVICES, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-0910246-B1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | PENN STATE RES FOUND (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| CN-1234718-C | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-01-04 | — | — | CN | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| CN-1464880-A | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-12-31 | — | — | CN | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | FGFR1 1575/4885SLC22A6 521/4885LMNA 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.